Carlos Gil Ferreira
BioClinica (United States)(US)Universidade Federal de Pernambuco(BR)MedSIR (Spain)(ES)Universidade Castelo Branco(BR)Instituto de Oncologia do Paraná(BR)Sociedade Brasileira de Oncologia Clínica(BR)University of Aveiro(PT)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics, RNA modifications and cancer, Head and Neck Cancer Studies
Most-Cited Works
- → Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial(2019)3,269 cited
- → Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial(2023)523 cited
- → IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy(2020)427 cited
- → Colorectal Cancer: Epidemiology, Disease Mechanisms and Interventions to Reduce Onset and Mortality(2016)364 cited
- Apoptosis: target of cancer therapy.(2002)
- → Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2(2013)237 cited